SCHEMBL2332272

SCHEMBL2332272

O=[N+]([O-])c1ccccc1-c1cccc(F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.65
ALDH1A1 P00352 3/20 0.65
EIF4E P06730 1/20 0.50
FBP1 P09467 3/20 0.48
ATM Q13315 1/20 0.46
HSPB1 P04792 1/20 0.45
S100A4 P26447 2/20 0.45
PTPRC P08575 1/20 0.45
GRM5 P41594 1/20 0.44
NPC1 O15118 1/20 0.43
CASP3 P42574 1/20 0.43
RAB9A P51151 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28019848 0.86 TDP1 (0.47) TDP1ALDH1A1EIF4EFBP1ATM
SCHEMBL20252200 0.86 ALDH1A1 (0.63) TDP1ALDH1A1EIF4EATMS100A4
SCHEMBL4142462 0.82 TDP1 (0.75) TDP1ALDH1A1S100A4PTPRCNPC1
SCHEMBL22637147 0.81 S100A4 (0.46) TDP1ALDH1A1EIF4EFBP1ATM
SCHEMBL29430799 0.81 S100A4 (0.46) TDP1ALDH1A1EIF4EFBP1ATM
SCHEMBL8051514 0.81 ALDH1A1 (0.67) TDP1ALDH1A1PTPRCNPC1RAB9A
SCHEMBL28012092 0.81 FBP1 (0.47) TDP1ALDH1A1EIF4EFBP1ATM
SCHEMBL2331432 0.80 TDP1 (0.71) TDP1ALDH1A1EIF4EATMS100A4
SCHEMBL27995417 0.80 FBP1 (0.41) TDP1ALDH1A1EIF4EFBP1ATM
SCHEMBL23282563 0.79 ALDH1A1 (0.65) TDP1ALDH1A1S100A4PTPRCNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-9108916-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2015-08-18 US disclosed
US-9108916-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2015-08-18 US disclosed
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, LLC (US) 2014-10-09 US disclosed
US-7772446-B2 Method for producing substituted biphenyls BASF SE (DE) 2010-08-10 US disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed
EP-1856024-B1 METHOD FOR PRODUCING SUBSTITUTED BIPHENYLS BASF SE (DE) 2008-08-06 EP disclosed
US-20080183021-A1 Method for Producing Substituted Biphenyls BASF SE (DE) 2008-07-31 US disclosed
EP-1856024-A1 METHOD FOR PRODUCING SUBSTITUTED BIPHENYLS BASF AKTIENGESELLSCHAFT (DE) 2007-11-21 EP disclosed
WO-2006092429-A1 METHOD FOR PRODUCING SUBSTITUTED BIPHENYLS BASF AKTIENGESELLSCAHFT (DE) 2006-09-08 WO disclosed
US-6362380-B1 REACTING 2-NITROCHLOROBENZENE AND A BORONIC ACID ; PALLADIUM CATALYST BASF AKTIENGESELLSCHAFT (DE) 2002-03-26 US disclosed
EP-0888261-B1 PROCESS FOR PREPARING NITROBIPHENYLENE BASF AG (DE) 2001-11-28 EP disclosed
EP-0888261-A1 PROCESS FOR PREPARING NITROBIPHENYLENE BASF AKTIENGESELLSCHAFT (DE) 1999-01-07 EP disclosed
WO-1997033846-A1 PROCESS FOR PREPARING NITROBIPHENYLENE BASF AKTIENGESELLSCHAFT (DE) 1997-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TDP1 1323/4885ALDH1A1 633/4885EIF4E 4009/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TDP1 1323/4885ALDH1A1 633/4885EIF4E 4009/4885
US-20080183021-A1 Method for Producing Substituted Biphenyls CBR3, DDT, HRH3 TDP1 1458/4885ALDH1A1 2309/4885EIF4E 4735/4885
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TDP1 1323/4885ALDH1A1 633/4885EIF4E 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.